RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000019.xml
Fortschr Neurol Psychiatr 2008; 76(5): 294-308
DOI: 10.1055/s-2008-1038151
DOI: 10.1055/s-2008-1038151
Fort- und Weiterbildung
© Georg Thieme Verlag Stuttgart · New York
Bipolare affektive Störungen
Teil II: Genetik, Kognition und Therapie
Bipolar Affective DisordersPart II: Genetics, Cognition and Therapy
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
28. April 2008 (online)
![](https://www.thieme-connect.de/media/fdn/200805/lookinside/thumbnails/10.1055-s-2008-1038151-1.jpg)
Lernziele
In unserem ersten Artikel zum Thema hatten wir Diagnostik, Epidemiologie und Verlauf bipolarer Erkrankungen dargestellt [1]. Der nachfolgende zweite Teil widmet sich Genetik, Kognition und Therapie. Ziel dieses Artikels ist es, neben neueren Erkenntnissen zur Neurobiologie differenzielle und evidenzbasierte Strategien der Therapie bipolar affektiver Störungen aufzuzeigen. Dabei wird neben der Psychopharmakotherapie auch der Aspekt der Psychotherapie und Psychoedukation sowie der gemeindepsychiatrischen Versorgung diskutiert.
Literatur
- 1 Brieger P. Bipolare affektive Störungen. Teil I: Diagnostik, Epidemiologie und Verlauf. Fortschr Neurol Psychiatr. 2007; 75 673-684
- 2 Craddock N, Forty L. Genetics of affective (mood) disorders. Eur J Hum Genet. 2006; 14 660-668
- 3 Kato T. Molecular genetics of bipolar disorder and depression. Psychiatry and Clinical Neurosciences. 2007; 61 3-19
- 4 Schulze T G, Hedeker D, Zandi P, Rietschel M, McMahon F J. What Is Familial About Familial Bipolar Disorder? Resemblance Among Relatives Across a Broad Spectrum of Phenotypic Characteristics. Archives of General Psychiatry. 2006; 63 1368-1376
- 5 Lerer B, Segman R H. Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation. Dialogues Clin Neurosci. 2006; 8 85-94
- 6 Alda M, Grof P, Rouleau G A, Turecki G, Young L T. Investigating responders to lithium prophylaxis as a strategy for mapping susceptibility genes for bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29 1038-1045
- 7 Einat H, Yuan P, Szabo S T, Dogra S, Manji H K. Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology. 2007; 55 123-131
- 8 Zobel A, Maier W. Endophänotypen - ein neues Konzept zur biologischen Charakterisierung psychischer Störungen. Der Nervenarzt. 2004; 75 205-214
- 9 Akiskal H S, Brieger P, Mundt C, Angst J, Marneros A. Temperament und affektive Störungen. Die TEMPS-A-Skala als Konvergenz europäischer und US-amerikanischer Konzepte. Nervenarzt. 2002; 73 262-271
- 10 Chiaroni P, Hantouche E G, Gouvernet J, Azorin J M, Akiskal H S. The cyclothymic temperament in healthy controls and familially at risk individuals for mood disorder: endophenotype for genetic studies?. J Affect Disord. 2005; 85 135-145
- 11 Hallam K T, Olver J S, Chambers V. et al . The heritability of melatonin secretion and sensitivity to bright nocturnal light in twins. Psychoneuroendocrinology. 2006; 31 867-875
- 12 Hajek T, Carrey N, Alda M. Neuroanatomical abnormalities as risk factors for bipolar disorder. Bipolar Disord. 2005; 7 393-403
- 13 Drevets W C. Neuroimaging studies of mood disorders. Biological Psychiatry. 2000; 48 813-829
- 14 Scherk H, Reith W, Falkai P. Hirnstrukturelle Veränderungen bei bipolaren affektiven Störungen. Nervenarzt. 2004; 75 861-872
- 15 Savitz J, Solms M, Ramesar R. Neuropsychological dysfunction in bipolar affective disorder: a critical opinion. Bipolar Disorders. 2005; 7 216-235
- 16 Strakowski S M, Delbello M P, Adler C M. The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings. Mol Psychiatry. 2005; 10 105-116
- 17 Basso M R, Lowery N, Neel J, Purdie R, Bornstein R A. Neuropsychological impairment among manic, depressed, and mixed-episode inpatients with bipolar disorder. Neuropsychology. 2002; 16 84-91
- 18 Olley A, Malhi G S, Batchelor J. et al . Executive functioning and theory of mind in euthymic bipolar disorder. Bipolar Disorders. 2005; 7 43-52
- 19 Martinez-Aran A, Vieta E, Colom F. et al . Neuropsychological performance in depressed and euthymic bipolar patients. Neuropsychobiology. 2002; 46 Suppl 1 16-21
- 20 Clark L, Iversen S D, Goodwin G M. A neuropsychological investigation of prefrontal cortex involvement in acute mania. American Journal of Psychiatry. 2001; 158 1605-1611
- 21 Murphy F C, Rubinsztein J S, Michael A. et al . Decision-making cognition in mania and depression. Psychol Med. 2001; 31 679-693
- 22 Malhi G S, Ivanovski B, Hadzi-Pavlovic D. et al . Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia. Bipolar Disord. 2007; 9 114-125
- 23 Martinez-Aran A, Vieta E, Reinares M. et al . Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. American Journal of Psychiatry. 2004; 161 262-270
- 24 Nehra R, Chakrabarti S, Pradhan B K, Khehra N. Comparison of cognitive functions between first- and multi-episode bipolar affective disorders. J Affect Disord. 2006; 93 185-192
- 25 Robinson L J, Ferrier I N. Evolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional evidence. Bipolar Disord. 2006; 8 103-116
- 26 Dittmann S, Seemuller F, Schwarz M J. et al . Association of cognitive deficits with elevated homocysteine levels in euthymic bipolar patients and its impact on psychosocial functioning: preliminary results. Bipolar Disord. 2007; 9 63-70
- 27 Altshuler L L, Ventura J, Gorp W van G. et al . Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects. Biological Psychiatry. 2004; 56 560-569
- 28 Torrent C, Martinez-Aran A, Amann B. et al . Cognitive impairment in schizoaffective disorder: a comparison with non-psychotic bipolar and healthy subjects. Acta Psychiatrica Scandinavica. 2007; 116 453-460
- 29 Borkowska A, Rybakowski J K. Neuropsychological frontal lobe tests indicate that bipolar depressed patients are more impaired than unipolar. Bipolar Disorders. 2001; 3 88-94
- 30 Martinez-Aran A, Vieta E, Torrent C. et al . Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipolar Disord. 2007; 9 103-113
- 31 Dickerson F B, Boronow J J, Stallings C R. et al . Association between cognitive functioning and employment status of persons with bipolar disorder. Psychiatr Serv. 2004; 55 54-58
- 32 Laes J R, Sponheim S R. Does cognition predict community function only in schizophrenia?: A study of schizophrenia patients, bipolar affective disorder patients, and community control subjects. Schizophr Res. 2006; 84 121-131
- 33 Tohen M, Zarate Jr C A, Hennen J. et al . The McLean-Harvard First-Episode Mania Study: Prediction of Recovery and First Recurrence. Am J Psychiatry. 2003; 160 2099-2107
- 34 Brieger P, Rottig S, Rottig D, Marneros A, Priebe S. Dimensions underlying outcome criteria in bipolar I disorder. Journal of Affective Disorders. 2007; 99 1-7
- 35 Tohen M, Bowden C L, Calabrese J R. et al . Influence of sub-syndromal symptoms after remission from manic or mixed episodes. Br J Psychiatry. 2006; 189 515-519
- 36 Fountoulakis K N, Vieta E, Sanchez-Moreno J. et al . Treatment guidelines for bipolar disorder: a critical review. J Affect Disord. 2005; 86 1-10
- 37 American Psychiatric Association . Practice guideline for the treatment of patients with bipolar disorder (revision). American Journal of Psychiatry. 2002; 159 1-50
- 38 Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Bipolar Disorder . Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Aust N Z J Psychiatry. 2004; 38 280-305
- 39 Yatham L N, Kennedy S H, O'Donovan C. et al . Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord. 2006; 8 721-739
- 40 National Institute for Health and Clinical Excellence .NICE clinical guideline 38: Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. London: National Institute for Health and Clinical Excellence 2006
- 41 Goodwin F K. The biology of recurrence: new directions for the pharmacologic bridge. J Clin Psychiatry. 1989; 50 Suppl 40-44; discussion 45 - 47
- 42 Findling R L, Frazier T W, Youngstrom E A. et al . Double-blind, placebo-controlled trial of divalproex monotherapy in the treatment of symptomatic youth at high risk for developing bipolar disorder. J Clin Psychiatry. 2007; 68 781-788
- 43 Judd L L, Akiskal H S, Schettler P J. et al . Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry. 2005; 62 1322-1330
- 44 Gijsman H J, Geddes J R, Rendell J M, Nolen W A, Goodwin G M. Antidepressants for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials. Am J Psychiatry. 2004; 161 1537-1547
- 45 Ketter T A, Calabrese J R. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry. 2002; 63 146-151
- 46 Keck Jr P E, Calabrese J R, McQuade R D. et al . A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. 2006; 67 626-637
- 47 Keck Jr P E, Calabrese J R, McIntyre R S. et al . Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry. 2007; 68 1480-1491
- 48 Krüger S. Olanzapin in der Behandlung bipolarer affektiver Erkrankungen. Psychiatr Prax. 2006; 33 Suppl 1 S18-26
- 49 Geddes J R, Burgess S, Hawton K, Jamison K, Goodwin G M. Long-Term Lithium Therapy for Bipolar Disorder: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Psychiatry. 2004; 161 217-222
- 50 Goodwin G M, Bowden C L, Calabrese J R. et al . A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry. 2004; 65 432-441
- 51 Ghaemi S N, Gilmer W S, Goldberg J F. et al . Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry. 2007; 68 1840-1844
- 52 Bowden C L, Calabrese J R, McElroy S L. et al . A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry. 2000; 57 481-489
- 53 Gyulai L, Bowden C L, McElroy S L. et al . Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology. 2003; 28 1374-1382
- 54 Dando T M, Keating G M. Quetiapine: a review of its use in acute mania and depression associated with bipolar disorder. Drugs. 2005; 65 2533-2551
- 55 Severus W E, Kleindienst N, Seemuller F. et al .What is the optimal serum lithium level in the long-term treatment of bipolar disorder? A review. Bipolar Disord im Druck
- 56 Zarate Jr C A, Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry. 2004; 161 169-171
- 57 Okuma T, Inanaga K, Otsuki S. et al . A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology (Berl). 1981; 73 95-96
- 58 Greil W, Ludwig-Mayerhofer W, Erazo N. et al . Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomised study. J Affect Disord. 1997; 43 151-161
- 59 Calabrese J R, Keck Jr P E, Macfadden W. et al . A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005; 162 1351-1360
- 60 Tohen M, Vieta E, Calabrese J. et al . Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003; 60 1079-1088
- 61 Sachs G S, Nierenberg A A, Calabrese J R. et al . Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007; 356 1711-1722
- 62 Calabrese J R, Bowden C L, Sachs G S. et al . A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 1999; 60 79-88
- 63 Brown E B, McElroy S L, Keck Jr P E. et al . A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry. 2006; 67 1025-1033
- 64 Vieta E, Calabrese J R, Goikolea J M, Raines S, Macfadden W. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2007; 9 413-425
- 65 Zarate Jr C A, Payne J L, Singh J. et al . Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry. 2004; 56 54-60
- 66 Goldberg J F, Burdick K E, Endick C J. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry. 2004; 161 564-566
- 67 Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry. 2006; 188 46-50
- 68 Frye M A, Grunze H, Suppes T. et al . A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007; 164 1242-1249
- 69 Bschor T, Lewitzka U, Sasse J. et al . Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic and endocrine mechanisms. Pharmacopsychiatry. 2003; 36 Suppl 3 S230-234
- 70 Nolen W A, Kupka R W, Hellemann G. et al . Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. Acta Psychiatr Scand. 2007; 115 360-365
- 71 Gajwani P, Kemp D E, Muzina D J. et al . Acute treatment of mania: an update on new medications. Curr Psychiatry Rep. 2006; 8 504-509
- 72 Scherk H, Pajonk F G, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry. 2007; 64 442-455
- 73 Licht R W. Limitations in randomised controlled trials evaluating drug effects in mania. Eur Arch Psychiatry Clin Neurosci. 2001; 251 Suppl 2 II66-71
- 74 Colom F, Vieta E, Tacchi M J, Sanchez-Moreno J, Scott J. Identifying and improving non-adherence in bipolar disorders. Bipolar Disord. 2005; 7 Suppl 5 24-31
- 75 Meyer T D, Hautzinger M. Psychoedukation und Psychotherapie. In: DGBS (ed). Weißbuch Bipolare Störungen in Deutschland Stand des Wissens - Defizite - Was ist zu tun? 2. überarbeitete Auflage ed. Hamburg: ConferencePoint Verlag 2006: 325-298
- 76 Scott J, Colom F, Vieta E. A meta-analysis of relapse rates with adjunctive psychological therapies compared to usual psychiatric treatment for bipolar disorders. Int J Neuropsychopharmacol. 2007; 10 123-129
- 77 Colom F, Vieta E, Martinez-Aran A. et al . A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry. 2003; 60 402-407
- 78 Meyer T, Hautzinger M. Manisch-depressive Störungen. Weinheim: Beltz PVU 2004
- 79 Schaub A, Bernhard B, Gauck L. Kognitiv-psychoedukative Therapie bei bipolaren Erkrankungen. Ein Therapiemanual. Göttingen: Hogrefe 2004
- 80 Wagner P, Bräunig P. Psychoedukation bei bipolaren Störungen. Ein Therapiemanual für Gruppen. Stuttgart: Schattauer 2006
- 81 Scott J, Paykel E, Morriss R. et al . Cognitive-behavioural therapy for severe and recurrent bipolar disorders: Randomised controlled trial. Br J Psychiatry. 2006; 188 313-320
- 82 Miklowitz D J, Otto M W, Frank E. et al . Psychosocial Treatments for Bipolar Depression: A 1-Year Randomized Trial From the Systematic Treatment Enhancement Program. Arch Gen Psychiatry. 2007; 64 419-426
- 83 Brieger P, Becker T. Spezialisierung in der Gemeindepsychiatrie?. Die Psychiatrie. 2007; 4 216-220
- 84 Kunze H. Personenzentrierter Ansatz in der psychiatrischen Versorgung in Deutschland. Psycho. 1999; 25 728-735
Prof. Dr. Peter Brieger
Bezirkskrankenhaus Kempten
Freudental 1
87435 Kempten
eMail: peter.brieger@extern.uni-ulm.de